Eli Lilly and Company (NYSE:LLY) Shares Acquired by Redhawk Wealth Advisors Inc.

Redhawk Wealth Advisors Inc. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,038 shares of the company’s stock after acquiring an additional 170 shares during the period. Eli Lilly and Company makes up about 0.8% of Redhawk Wealth Advisors Inc.’s portfolio, making the stock its 29th biggest position. Redhawk Wealth Advisors Inc.’s holdings in Eli Lilly and Company were worth $5,812,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Alhambra Investment Management LLC increased its holdings in Eli Lilly and Company by 3.0% in the 1st quarter. Alhambra Investment Management LLC now owns 479 shares of the company’s stock worth $396,000 after acquiring an additional 14 shares in the last quarter. CX Institutional grew its holdings in shares of Eli Lilly and Company by 15.2% in the first quarter. CX Institutional now owns 27,223 shares of the company’s stock valued at $22,484,000 after purchasing an additional 3,600 shares during the period. Rockingstone Advisors LLC grew its holdings in shares of Eli Lilly and Company by 20.6% in the first quarter. Rockingstone Advisors LLC now owns 3,723 shares of the company’s stock valued at $3,075,000 after purchasing an additional 635 shares during the period. MV Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 7.7% in the first quarter. MV Capital Management Inc. now owns 2,466 shares of the company’s stock valued at $2,037,000 after purchasing an additional 177 shares during the period. Finally, Integral Investment Advisors Inc. acquired a new position in Eli Lilly and Company in the first quarter valued at about $986,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on LLY shares. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Guggenheim restated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Up 4.4%

Shares of LLY stock opened at $807.75 on Wednesday. The firm has a 50-day moving average price of $770.33 and a 200 day moving average price of $800.86. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a market capitalization of $765.54 billion, a price-to-earnings ratio of 68.98, a PEG ratio of 1.40 and a beta of 0.41. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter last year, the firm earned $2.58 EPS. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company’s payout ratio is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.